Propanc Biopharma Stock Scheduled to Reverse Split on Monday, October 26th (NASDAQ:PPCB)

Shares of Propanc Biopharma Inc (NASDAQ:PPCB) are scheduled to reverse split before the market opens on Monday, October 26th. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, October 25th.

Propanc Biopharma Price Performance

PPCB traded down $0.05 during trading hours on Thursday, hitting $0.27. 206,529 shares of the company’s stock were exchanged, compared to its average volume of 348,886. Propanc Biopharma has a 12-month low of $0.27 and a 12-month high of $38.25. The firm has a 50 day moving average of $0.78 and a 200 day moving average of $1.48.

Propanc Biopharma (NASDAQ:PPCB) last released its earnings results on Friday, September 25th. The company reported ($1.77) earnings per share (EPS) for the quarter.

Propanc Biopharma declared that its board has approved a stock buyback program on Thursday, July 2nd that allows the company to repurchase $500,000.00 in outstanding shares. This repurchase authorization allows the company to buy up to 15.2% of its shares through open market purchases. Stock repurchase programs are typically an indication that the company’s management believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut Propanc Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 26th. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, Propanc Biopharma currently has a consensus rating of “Sell”.

Propanc Biopharma Company Profile

Propanc Biopharma, Inc is a clinical-stage biotechnology company focused on developing novel treatments for solid tumors. The company’s research centers on proenzyme-based cancer therapies designed to target the tumor microenvironment and address cancer recurrence and metastasis.

Propanc’s lead investigational product is PRP, a formulation of two digestive proenzymes, trypsinogen and chymotrypsinogen. The company is developing PRP for potential use against advanced and recurrent cancers, including pancreatic, ovarian and colorectal cancers.